Abstract
Ocular surface disease is extremely common in glaucoma patients and a major cause of morbidity. This chapter describes the diagnosis and management of three patients with increasing severity of ocular surface disease. In addition to standard management of ocular surface disease, switching to non-preserved drops is one of the first-line therapies that can have a beneficial effect. In more extreme cases, such as medication-induced cicatricial conjunctivitis and limbal stem cell deficiency, consideration should be given to stopping all topical medication and using oral agents and/or laser procedures to reduce the need for topical therapy (Box 1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–5.
Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1–9.
Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eye drops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–34.
Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 2011;28(4):267–82.
Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418–23.
Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Tomidokoro A, Aihara M, Amano S. Effects of long-term topical antiglaucoma medications on meibomian glands. Graefes Arch Clin Exp Ophthalmol. 2012;250(8):1181–5.
Lee SY, Wong TT, Chua J, Boo C, Soh YF, Tong L. Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity. Eye. 2013;27(10):1142–50.
Mastropasqua R, Agnifili L, Fasanella V, Curcio C, Brescia L, Lanzini M, Fresina M, Mastropasqua L, Marchini G. Corneoscleral limbus in glaucoma patients: in vivo confocal microscopy and immunocytological study. Invest Ophthalmol Vis Sci. 2015;56(3):2050–8.
Baudouin C. Allergic reaction to topical eye drops. Curr Opin Allergy Clin Immunol. 2005;5(5):459–63.
Pellinen P, Huhtala A, Tolonen A, Lokkila J, Mäenpää J, Uusitalo H. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo. Curr Eye Res. 2012;37(2):145–54.
Gandolfi S, Paredes T, Goldberg I, Coote M, Wells A, Volksone L, Pillai MR, Stalmans I, Denis P. Travoprost Bak-Free Clinical Study Group. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol. 2012;22(1):34–44.
Janulevičienė I, Derkač I, Grybauskiene L, Paulauskaitė R, Gromnickaite R, Kuzmienė L. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol. 2012;6:103–9.
Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol. 2012;6:441–6.
Baudouin C. Glaucoma and ocular surface disease: who, why and how to treat? View Glaucoma. 2013;8(1):4–10.
Cho HK, Park MH, Moon JI. The effect of additional topical cyclosporin or vitamin A on the ocular surface during antiglaucoma medication administration. Ophthalmic Res. 2012;48(3):139–45.
Saini M, Dhiman R, Dada T, Tandon R, Vanathi M. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye. 2015;29(6):808–14.
Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004;111(1):45–52.
Ahmed M, Zein G, Khawaja F, Foster CS. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res. 2004;23(6):579–92.
Tsai JH, Derby E, Holland EJ, Khatana AK. Incidence and prevalence of glaucoma in severe ocular surface disease. Cornea. 2006;25(5):530–2.
Holland EJ, Schwartz GS. The Paton lecture: ocular surface transplantation: 10 years’ experience. Cornea. 2004;23(5):425–31.
Schwartz GS, Holland EJ. Iatrogenic limbal stem cell deficiency: when glaucoma management contributes to corneal disease. J Glaucoma. 2001;10(6):443–5.
Alvarenga LS, Mannis MJ, Brandt JD, Lee WB, Schwab IR, Lim MC. The long-term results of keratoplasty in eyes with a glaucoma drainage device. Am J Ophthalmol. 2004;138(2):200–5.
Lim KS. Corneal endothelial cell damage from glaucoma drainage device materials. Cornea. 2003;22(4):352–4.
Acknowledgments
Financial Disclosures: None of the authors have any financial disclosures regarding the contents discussed in this manuscript.
Conflict of Interest: None of the authors have any conflicts of interest with the contents discussed in this manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Ghahari, E., Djalilian, A.R., Aref, A.A. (2018). Management of Glaucoma in Patients with Ocular Surface Disease. In: Djalilian, A. (eds) Ocular Surface Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-15823-5_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-15823-5_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-15822-8
Online ISBN: 978-3-319-15823-5
eBook Packages: MedicineMedicine (R0)